Learn due diligence best practices from leading global pharmaceutical professionals in this Q&A white paper on how to form productive biopharma partnerships.

This white paper discusses...

  • What large pharma expects when entering due diligence with a biopharma company
  • The importance of IP due diligence
  • The best ways to present and stage information that is disclosed to a potential partner
  • Common mistakes and how to avoid them 
  • How to recognize potential problems and address them early in the process
  • The best practices for the best long-term partnerships

If you are seeking to partner with another biopharmaceutical company, or desire to out- or in-license a drug, you will want to hear these perspectives.


the white paper




ShareVault’s secure document sharing solution gives pharmaceutical and biotechnology  organizations the confidence to simply and securely share sensitive documents with third parties during due diligence, product development, technology transfers, fundraising, partnering, collaborative research and other activities that require the highest level of document security.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.